PMID- 26417884
OWN - NLM
STAT- MEDLINE
DCOM- 20180105
LR  - 20181202
IS  - 1520-6777 (Electronic)
IS  - 0733-2467 (Linking)
VI  - 36
IP  - 1
DP  - 2017 Jan
TI  - Predictive factors of adverse events after intravesical suburothelial 
      onabotulinumtoxina injections for overactive bladder syndrome-A real-life 
      practice of 290 cases in a single center.
PG  - 142-147
LID - 10.1002/nau.22892 [doi]
AB  - AIMS: Patients often experience adverse events (AEs) after intravesical 
      onabotulinumtoxinA (BoNT-A) treatment for overactive bladder refractory to 
      antimuscarinic agents. We investigated the prevalence and predictive factors of 
      AEs in such patients. METHODS: A total of 290 patients underwent intravesical 
      BoNT-A (100 U) suburothelial injection. The age, gender, overactive bladder 
      subtypes, medical co-morbidities, and neurological diseases of the patients were 
      recorded. The maximum flow rate (Q(max) ), voided volume, post-void residual 
      (PVR) volume, and voiding efficiency (VE) at baseline were analyzed to identify 
      adverse events within 3 months after treatment. RESULTS: Acute urinary retention 
      (AUR) developed in 24 patients (8.3%), and urinary tract infection (UTI) occurred 
      in 44 (15.2%) within 3 months of treatment. Large PVR volume (>200 ml) occurred 
      in 81 (27.9%), 68 (24.3%), and 49 (18.4%) patients 1, 3, and 6 months after 
      treatment, respectively. AUR developed significantly more often in men, patients 
      >61 years old, those with a baseline Q(max) </=15 ml/sec, PVR >/=100 ml, and VE <90%. 
      Patients older than 61 years had a higher incidence of large PVR 1 month after 
      treatment. Female gender and a baseline PVR volume >/=100 ml had a greater 
      incidence of UTI. Age >61 years, low Q(max) , low voiding efficiency, and large 
      PVR at baseline were also risk factors for adverse events. CONCLUSION: AUR, UTI, 
      and large PVR volume are common AEs after BoNT-A treatment. Patients with 
      overactive bladders that are at risk of developing AEs after BoNT-A injection 
      should be informed of the possible AEs. Neurourol. Urodynam. 36:142-147, 2017. (c) 
      2015 Wiley Periodicals, Inc.
CI  - (c) 2015 Wiley Periodicals, Inc.
FAU - Jiang, Yuan-Hong
AU  - Jiang YH
AD  - Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, 
      Hualien, Taiwan.
FAU - Ong, Hueih-Ling
AU  - Ong HL
AD  - Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, 
      Hualien, Taiwan.
FAU - Kuo, Hann-Chorng
AU  - Kuo HC
AD  - Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, 
      Hualien, Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20150928
PL  - United States
TA  - Neurourol Urodyn
JT  - Neurourology and urodynamics
JID - 8303326
RN  - 0 (Neuromuscular Agents)
RN  - EC 3.4.24.69 (Botulinum Toxins, Type A)
SB  - IM
MH  - Administration, Intravesical
MH  - Age Factors
MH  - Aged
MH  - Botulinum Toxins, Type A/administration & dosage/*adverse effects/therapeutic use
MH  - Comorbidity
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neuromuscular Agents/administration & dosage/*adverse effects/therapeutic use
MH  - Prevalence
MH  - Prognosis
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Sex Factors
MH  - Treatment Outcome
MH  - Urinary Bladder/pathology
MH  - Urinary Bladder, Overactive/*complications/drug therapy/pathology
MH  - Urodynamics
MH  - Urothelium
OTO - NOTNLM
OT  - aging
OT  - lower urinary tract dysfunction
OT  - overactive bladder
EDAT- 2015/09/30 06:00
MHDA- 2018/01/06 06:00
CRDT- 2015/09/30 06:00
PHST- 2015/06/28 00:00 [received]
PHST- 2015/09/15 00:00 [accepted]
PHST- 2015/09/30 06:00 [pubmed]
PHST- 2018/01/06 06:00 [medline]
PHST- 2015/09/30 06:00 [entrez]
AID - 10.1002/nau.22892 [doi]
PST - ppublish
SO  - Neurourol Urodyn. 2017 Jan;36(1):142-147. doi: 10.1002/nau.22892. Epub 2015 Sep 
      28.